Chapter 002

Pharmacokinetics: The Absorption, Distribution, and Fate of Drugs

John A. Yagiela

CITED REFERENCES

  1. Agre P, King LS, Yasui M, et al: Aquaporin water channels—from atomic structure to clinical medicine. J Physiol 542.1:3-16, 2002.
  2. Alayli G, Cengiz K, Cantürk F, et al: Acute myopathy in a patient with concomitant use of pravastatin and colchicine. Ann Pharmacother 39:1358-1361, 2005. PUBMED Abstract
  3. Bachmakov I, Glaeser H, Fromm MF, et al: Interaction of oral antidiabetic drugs with hepatic uptake transporters. Diabetes 57:1463-1469, 2008. PUBMED Abstract
  4. Barchowsky A, Stargel WW, Shand DG, et al: Saliva concentrations of lidocaine and its metabolites in man. Ther Drug Monit 4:335-339, 1982. PUBMED Abstract
  5. Bartnicka L, Kurzawski M, Drozdzik A, et al: Effect of ABCB1 (MDR1) 3435C>T and 2677G>A, T polymorphisms and P-glycoprotein inhibitors on salivary digoxin secretion in congestive heart failure patients. Pharmacol Rep 59:323-329, 2007.
  6. Beckett AH, Hossie RD: Buccal absorption of drugs. In Brodie BB, Gillette JR, editors: Handbook of experimental pharmacology, Berlin, 1971, Springer-Verlag.
  7. Berlin CM, Jr: Pharmacologic considerations of drug use in the lactating mother. Obstet Gynecol 58(suppl):17S-23S, 1981. PUBMED Abstract
  8. Bretscher MS: The molecules of the cell membrane. Sci Am 253:100-108, 1985. PUBMED Abstract
  9. Cucinell SA, Conney AH, Sansur M, et al: Drug interactions in man. I. Lowering effect of phenobarbital on plasma levels of bishydroxycoumarin (Dicumarol) and diphenylhydantoin (Dilantin). Clin Pharmacol Ther 6:420-429, 1965.
  10. Evans WE, Relling MV: Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286:487-491, 1999.
  11. Feller K, le Petit G: On the distribution of drugs in saliva and blood plasma. Int J Clin Pharmacol Biopharm 15:468-469, 1977.
  12. Fisher DM: (Almost) everything you learned about pharmacokinetics was (somewhat) wrong! Anesth Analg 83:901-903, 1996. PUBMED Abstract
  13. Gangarosa LP, Sr: Iontophoresis for surface local anesthesia. J Am Dent Assoc 88:125-128, 1974.
  14. Germain P, Staels B, Dacquet C, et al: Overview of nomenclature of nuclear receptors. Pharmacol Rev 58:685-704, 2006. PUBMED Abstract
  15. Gibaldi M: Biopharmaceutics and clinical pharmacokinetics, ed 3, Philadelphia, 1984, Lea & Febiger.
  16. Greenblatt DJ, Koch-Weser J: Clinical toxicity of chlordiazepoxide and diazepam in relation to serum albumin concentration: a report from the Boston Collaborative Drug Surveillance Program. Eur J Clin Pharmacol 7:259-262, 1974. PUBMED Abstract
  17. Gupta SK, Ellinwood EH, Nikaido AM, et al: Simultaneous modeling of the pharmacokinetic and pharmacodynamic properties of benzodiazepines. 1. Lorazepam. J Pharmacokinet Biopharm 18:89-102, 1990. PUBMED Abstract
  18. Hahn TJ, Hendin BA, Scharp CR, et al: Serum 25-hydroxycalciferol levels and bone mass in children on chronic anticonvulsant therapy. N Engl J Med 292:550-553, 1975.
  19. Hogben CAM, Tocco DJ, Brodie BB, et al: On the mechanism of intestinal absorption of drugs. J Pharmacol Exp Ther 125:275-282, 1959.
  20. Hughes MA, Glass PSA, Jacobs JR: Context-sensitive half-time in multicompartment pharmacokinetic models for intravenous anesthetic drugs. Anesthesiology 76:334-341, 1992.
  21. Inman WHW, Adelstein AM: Rise and fall of asthma mortality in England and Wales in relation to use of pressurized aerosols. Lancet 2:279-285, 1969. PUBMED Abstract
  22. Kellermann G, Shaw CR, Luyten-Kellerman M: Aryl hydrocarbon hydroxylase inducibility and bronchogenic carcinoma. N Engl J Med 289:934-937, 1973. PUBMED Abstract
  23. Kemper EM, van Zandbergen AE, Cleypool C, et al: Increased penetration of paclitaxel into the brain by inhibition of P-glycoprotein. Clin Cancer Res 9:2849-2855, 2003. PUBMED Abstract
  24. King LS, Yasui M: Aquaporins and disease: lessons from mice to humans. Trends Endocrinol Metab 13:355-360, 2002. PUBMED Abstract
  25. Kivistö KT, Niemi M: Influence of drug transporter polymorphisms on pravastatin pharmacokinetics in humans. Pharm Res 24:239-247, 2007. PUBMED Abstract
  26. Levine RR: Pharmacology: drug actions and reactions, ed 4, Boston, 1990, Little, Brown.
  27. Levy G: Kinetics and implications of dissolution rate: limited gastrointestinal absorption of drugs. In Ariens EJ, editor: Physico-chemical aspects of drug action, Oxford, 1968, Pergamon Press.
  28. Lipinski CA, Lombardo F, Dominy BW, et al: Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 46:3-26, 2001. PUBMED Abstract
  29. Lovering EG, McGilveray IJ, McMillan I, et al: The bioavailability and dissolution behavior of nine brands of tetracycline tablets. Can J Pharm Sci 10:36-39, 1975.
  30. Marchetti S, Mazzanti R, Beijnen JH, et al: Concise review: clinical relevance of drug-drug and herb-drug interactions mediated by the ABC transporter ABCB1 (MDR1, P-glycoprotein). Oncologist 12:927-941, 2007. PUBMED Abstract
  31. Marier JR: Halogenated hydrocarbon environmental pollution: the special case of halogenated anesthetics. Environ Res 28:212-239, 1982. PUBMED Abstract
  32. Mark LC: Thiobarbiturates. In Papper EM, Kitz RJ, editors: Uptake and distribution of anesthetic agents, New York, 1963, McGraw-Hill.
  33. Melander A: Influence of food on the bioavailability of drugs. In Gibaldi M, Prescott L, editors: Handbook of clinical pharmacokinetics, New York, 1983, ADIS Health Science Press.
  34. Minshall RD, Malik AB: Transport across the endothelium: regulation of endothelial permeability. Handb Exp Pharmacol 176(Pt 1):107-144, 2006. PUBMED Abstract
  35. Mizuno N, Niwa T, Yotsumoto Y, et al: Impact of drug transporter studies on drug discovery and development. Pharmacol Rev 55:425-461, 2003. PUBMED Abstract
  36. Murthy KS, Talim ST, Singh I: A comparative evaluation of topical application and iontophoresis of sodium fluoride for desensitization of hypersensitive dentin. Oral Surg Oral Med Oral Pathol 36:448-458, 1973. PUBMED Abstract
  37. Nebert DW, Russell DW: Clinical importance of the cytochromes P450. Lancet 360:1155-1162, 2002. PUBMED Abstract
  38. Ohki S, Gravis C, Pant H: Permeability of axon membranes to local anesthetics. Biochim Biophys Acta 643:495-507, 1981.
  39. Okey AB, Roberts EA, Harper PA, et al: Induction of drug-metabolizing enzymes: mechanisms and consequences. Clin Biochem 19:132-141, 1986.
  40. Portenoy RK, Khan E, Layman M, et al: Chronic morphine therapy for cancer pain: plasma and cerebrospinal fluid morphine and morphine-6-glucuronide concentrations. Neurology 41:1457-1461, 1991.
  41. Pratt WB: The entry, distribution, and elimination of drugs. In Pratt WB, Taylor P, editors: Principles of drug action: the basis of pharmacology, ed 3, New York, 1990, Churchill Livingstone.
  42. Rapoport SI, Robinson PJ: Tight-junctional modification as the basis of osmotic opening of the blood-brain barrier. Ann N Y Acad Sci 481:250-267, 1986.
  43. Renton KW: Factors affecting drug biotransformation. Clin Biochem 19:72-75, 1986.
  44. Rosenberg MF, Callaghan R, Modok S, et al: Three-dimensional structure of P-glycoprotein. J Biol Chem 280:2857-2862, 2005.
  45. Roth RA: Biochemistry, physiology and drug metabolism—implications regarding the role of the lungs in drug disposition. Clin Physiol Biochem 3:66-79, 1985. PUBMED Abstract
  46. Rylance GW, Moreland TA: Saliva carbamazepine and phenytoin level monitoring. Arch Dis Child 56:637-640, 1981.
  47. Sakaeda T: MDR1 genotype-related pharmacokinetics: fact or fiction? Drug Metab Pharmacokinet 20:391-414, 2005. PUBMED Abstract
  48. Sarkadi B, Homolya L, Szakács G, et al: Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense system. Physiol Rev 86:1179-1236, 2006.
  49. Schekman R, Orci L: Coat proteins and vesicle budding. Science 271:1526-1533, 1996. PUBMED Abstract
  50. Scherrmann J-M: Drug delivery to brain via the blood-brain barrier. Vasc Pharmacol 38:349-354, 2002. PUBMED Abstract
  51. Singer SJ, Nicholson GL: The fluid mosaic model of the structure of cell membranes. Science 175:720-731, 1972. PUBMED Abstract
  52. Tanaka E: In vivo age-related changes in hepatic drug-oxidizing capacity in humans. J Clin Pharm Ther 23:247-255, 1998. PUBMED Abstract
  53. Van Dyke C, Jatlow P, Ungerer J, et al: Oral cocaine: plasma concentrations and central effects. Science 200:211-213, 1978. PUBMED Abstract
  54. Vesell ES: Advances in pharmacogenetics. Prog Med Genet 9:291-367, 1973. PUBMED Abstract
  55. Wood M: Plasma drug binding: implications for anesthesiologists. Anesth Analg 65:786-804, 1986. PUBMED Abstract

GENERAL REFERENCES

  1. Atkinson AJ Jr, Abernethy DR, Daniels CE, et al, editors: Principles of clinical pharmacology, ed 2, Amsterdam, 2007, Elsevier.
  2. Brunton LL, Lazo JS, Parker KL, editors: Goodman & Gilman’s the pharmacological basis of therapeutics, ed 11, New York, 2006, McGraw-Hill.
  3. Derendorf H, Hochhaus G, editors: Handbook of pharmacokinetic/pharmacodynamic correlation, Boca Raton, FL, 1995, CRC Press.
  4. Gibaldi M: Biopharmaceutics and clinical pharmacokinetics, ed 4, Philadelphia, 1991, Lea & Febiger.
  5. Katzung BG: Basic and clinical pharmacology, ed 10, New York, 2007, McGraw-Hill Professional.
  6. Pratt WB, Taylor P, editors: Principles of drug action: the basis of pharmacology, ed 3, New York, 1990, Churchill Livingstone.
  7. Walsh CT, Schwartz-Bloom RD: Levine’s pharmacology: drug actions and reactions, ed 7, New York, 2005, Taylor & Francis.